Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

16.91
+0.52003.17%
Pre-market: 16.910.0034+0.02%06:44 EDT
Volume:13.06M
Turnover:224.22M
Market Cap:13.49B
PE:-15.13
High:17.72
Open:16.59
Low:16.17
Close:16.39
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:1.41
T/O Rate:8.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:21.41
PE(LYR):-11.71

Loading ...

Stock Track | Summit Therapeutics Soars 5.42% Intraday on Citi Buy Rating and ASCO Catalyst Expectations

Stock Track
·
May 04

Roblox, Spotify, And Robinhood Are Among Top 10 Large-Cap Losers Last Week (April 27-May 1): Are The Others In Your Portfolio?

Benzinga_recent_news
·
May 03

Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider Losses - Has The Bull Case Changed?

Simply Wall St.
·
May 03

Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT)

TIPRANKS
·
May 03

Summit Therapeutics (SMMT) Receives a Rating Update from a Top Analyst

TIPRANKS
·
May 03

Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing

TIPRANKS
·
May 02

Summit Therapeutics Shares Fall After 1Q Loss Widens

Dow Jones
·
May 02

BUZZ-Summit Therapeutics falls after interim results from lung cancer study

Reuters
·
May 02

Summit Therapeutics Stock Dips After Q1 Financial Report

Benzinga Earnings
·
May 01

Summit Therapeutics falls -27.4%

TIPRANKS
·
May 01

Goldman Sachs Remains a Buy on Summit Therapeutics (SMMT)

TIPRANKS
·
May 01

Summit Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 01

Summit Therapeutics Q1 FY26 net loss widens to $189.4 million; operating expenses rise to $195.2 million

Reuters
·
May 01

Summit Therapeutics Q1 adjusted loss narrows despite higher R&D costs

Reuters
·
May 01

Summit Therapeutics Q1 Adjusted EPS USD -0.15 VS. Ibes Estimate USD -0.18

THOMSON REUTERS
·
May 01

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

THOMSON REUTERS
·
May 01

Electric Vehicle Adoption Reaches 'Tipping Point' Globally, Trend Deemed Self-Sustaining

Deep News
·
Apr 26

Summit Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Apr 23

Summit partner selection for ASCO plenary signals strong OS, says Leerink

TIPRANKS
·
Apr 22

Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim

TIPRANKS
·
Apr 22